Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Donafenib and Sintilimab in First-line Treatment of Unresectable ICC
NCT05348811Phase 2Completed
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jun 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and sintilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2022; status: completed.
02
Drugs
donafenibsintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05348811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348811.